1. Phylogeny  
   Mitogen‐activated protein kinase 3 (MAPK3), commonly known as ERK1, is a conventional member of the MAP kinase family belonging to the CMGC group of serine/threonine kinases. ERK1 is evolutionarily conserved across metazoans and is found in all vertebrates, where it typically exists alongside its closely related isoform ERK2 (MAPK1) that arose from a gene duplication event in the common ancestor of bony vertebrates. Comparative analyses have shown that ERK1 and ERK2 retain high sequence similarity in their catalytic domains, yet differential evolutionary forces are evident; ERK1 has evolved at a slightly faster rate than ERK2, potentially due to its smaller gene size and differences in regulatory complexity. Phylogenetic studies place ERK1 within the well‐characterized conventional MAP kinases which include subsets activated by the canonical Ras–Raf–MEK–ERK cascade, underscoring its integral role in the propagation of mitogenic and stress signals. Foundational studies on protein kinase evolution, as detailed by Manning et al. (2002) and subsequent reviews, support the assignment of ERK1 to an evolutionary core set of kinases that emerged in early eukaryotes and have maintained critical roles through complex multicellular evolution (martinvega2023navigatingtheerk12 pages 1-2, krishna2008thecomplexityof pages 1-2, pearson2001mitogenactivatedprotein(map) pages 1-2).
2. Reaction Catalyzed  
   MAPK3/ERK1 is an ATP-dependent serine/threonine kinase that catalyzes the phosphorylation of specific protein substrates. The chemical reaction that ERK1 mediates is:  
     ATP + [protein]-(L-serine or L-threonine) → ADP + [protein]-(L-serine/threonine)-phosphate + H⁺  
   This reaction involves the transfer of the γ-phosphate group from ATP to the hydroxyl group of a serine or threonine residue in the substrate protein, a process that is fundamental to the regulation of numerous cellular processes (pearson2001mitogenactivatedprotein(map) pages 2-2).
3. Cofactor Requirements  
   The kinase activity of MAPK3/ERK1 is dependent upon the presence of divalent metal ions that serve as essential cofactors. In particular, Mg²⁺ is required to coordinate ATP binding and facilitate the transfer of the phosphate group during the catalytic reaction. This cofactor dependency is characteristic of most protein kinases and is critical for stabilizing the transition state of the phosphoryl transfer reaction (pearson2001mitogenactivatedprotein(map) pages 2-2).
4. Substrate Specificity  
   MAPK3/ERK1 is classified as a proline‐directed kinase, displaying a marked specificity for phosphorylating serine/threonine residues when immediately followed by a proline residue. The minimal consensus motif recognized by ERK1 is [S/T]-P, and additional substrate recognition is facilitated by docking interactions mediated through short linear motifs present in target proteins. These docking motifs, typically referred to as D domains (or CD motifs) and F-recruitment sites (FRS), enhance the affinity and selectivity of ERK1 towards its substrates. Although thousands of phosphorylation sites have been mapped in cellular systems, about 160 bona fide substrates have been experimentally validated for ERK1, encompassing transcription factors, cytoskeletal regulators, and other kinases that further propagate downstream signaling. Recent studies using high-resolution phosphoproteomic analyses have underscored that substrate specificity is a function not only of the minimal phosphorylation motif but also of additional flanking residues—for instance, preferential amino acid sequences may include elements such as [P/L/V/I]-X-[S/T]-P-X-[K/R] in some substrates. Such specificity profiles have been comprehensively mapped for the human serine/threonine kinome in recent atlases that provide detailed substrate motif information. (Johnson2023Atlas, Yaron-Barir2024Atlas)
5. Structure  
   The three-dimensional organization of MAPK3/ERK1 is highly conserved within the MAP kinase family and features a typical two-lobe kinase structure. The N-terminal lobe of ERK1 contains a predominantly β-sheet architecture with an ATP-binding pocket, whereas the larger C-terminal lobe is mainly α-helical and houses the substrate recognition site. A defining feature of ERK1 is the activation loop, which includes the conserved Thr-Glu-Tyr (TEY) motif; dual phosphorylation of the threonine and tyrosine residues within this loop triggers a conformational rearrangement necessary for full catalytic activation. Structural studies have revealed that phosphorylation induces domain closure and repositions key secondary structural elements, such as the C-helix, thereby assembling a hydrophobic spine essential for substrate binding and catalysis (martinvega2023navigatingtheerk12 pages 4-5, pearson2001mitogenactivatedprotein(map) pages 4-4).

In addition to the catalytic core, ERK1 contains a conserved acidic common docking (CD) domain that is critical for interactions with upstream kinase activators (such as MEK1/2) and regulatory phosphatases (such as DUSP6), as well as for binding substrates that harbor complementary docking motifs. A feature unique to ERK isoforms is the presence of an N-terminal alanine-rich (NTAR) sequence that enhances translation fidelity and is thought to contribute to the fine-tuning of ERK1 expression levels. Other structural elements, such as the MAP kinase insert, further contribute to its regulation by mediating complex formation with scaffold proteins and influencing subcellular localization (martinvega2023navigatingtheerk12 pages 5-7, meloche2007theerk12mitogenactivated pages 13-13).

1. Regulation  
   The activity of MAPK3/ERK1 is controlled by multiple regulatory mechanisms that ensure precise control of signal transduction downstream of mitogenic stimuli. ERK1 is activated by dual phosphorylation on its TEY motif within the activation loop by upstream dual-specificity kinases MEK1 and MEK2. This phosphorylation event increases its catalytic activity dramatically, often by several orders of magnitude, and serves as the principal switch for turning on downstream signaling events (roberts2007targetingtherafmekerk pages 1-2, martinvega2023navigatingtheerk12 pages 4-5).

Inactivation of ERK1 is mediated by a set of dual-specificity phosphatases (DUSPs) including DUSP1, DUSP4, and DUSP6, which dephosphorylate the activation loop, thus attenuating its kinase activity. Regulatory feedback loops are also prominent: ERK1 can phosphorylate upstream components of its own cascade, such as MEK and RAF, thereby creating a negative feedback that modulates the intensity and duration of the signal (krishna2008thecomplexityof pages 10-12, roberts2007targetingtherafmekerk pages 2-3).

Furthermore, ERK1 function is modulated by its interactions with scaffold proteins, such as KSR and IQGAP, which localize kinase modules to specific subcellular compartments and facilitate efficient signal transduction. These scaffold proteins are critical for determining substrate accessibility and can also protect ERK1 from premature dephosphorylation. In addition to classical phosphorylation-dependent activation, non-catalytic functions have emerged whereby ERK1 participates in allosteric regulation of target proteins and modulates transcription by directly interacting with DNA-associated factors in the nucleus (martinvega2023navigatingtheerk12 pages 45-46, krishna2008thecomplexityof pages 10-12).

1. Function  
   MAPK3/ERK1 is an essential serine/threonine kinase involved in the propagation of signals from cell surface receptors through the Ras-Raf-MEK-ERK cascade. It plays a pivotal role in regulating a broad range of biological processes that include cell growth, adhesion, survival, differentiation, and the regulation of the cell cycle. In response to growth factors, cytokines, and other extracellular stimuli, ERK1 phosphorylates a variety of substrates that are distributed among the cytoplasm, nucleus, and other subcellular organelles. Many of these substrates are transcription factors—such as ATF2, ELK1, FOS, and SPZ1—whose phosphorylation by ERK1 modulates gene expression required for cell proliferation and differentiation (coulombe2007atypicalmitogenactivatedprotein pages 1-2, martinvega2023navigatingtheerk12 pages 1-2).

Additionally, ERK1 influences regulatory pathways in the cytosol by phosphorylating components involved in translation (e.g., EIF4EBP1), cytoskeletal dynamics (e.g., CTTN, PXN), apoptosis (e.g., BAD, CASP9), and endosomal trafficking. Its role in coordinating the timing of cell cycle transitions, especially the G1-to-S phase progression, underscores its importance in cell cycle regulation as well as its misregulation in various cancers. ERK1 is also implicated in the modulation of other protein kinases—such as members of the RSK and MSK families—thereby extending its impact on cellular signal amplification and integration of metabolic, apoptotic, and stress responses (roberts2007targetingtherafmekerk pages 3-5, martinvega2023navigatingtheerk12 pages 7-8).

Due to its ubiquitous expression and central role in mitogenic signaling, ERK1 is expressed in a wide variety of tissues ranging from proliferative cells in the developing embryo to differentiated cells in adult tissues. Its activity is required not only for normal cellular physiology but also for pathological conditions such as oncogenesis, where hyperactivation of the MAPK/ERK cascade can lead to uncontrolled cell proliferation and survival (coulombe2007atypicalmitogenactivatedprotein pages 1-2, roberts2007targetingtherafmekerk pages 1-2).

1. Other Comments  
   Several inhibitors have been developed to target the MAPK/ERK cascade at various points, including MEK inhibitors and direct ERK inhibitors, which have found application in the treatment of cancers characterized by aberrant upstream activation—for example, mutations in receptor tyrosine kinases, RAS, or RAF that lead to constitutive ERK activation. Although direct mutations in MAPK3/ERK1 are less commonly reported in patient samples compared to upstream alterations, the pathway as a whole is a prominent target for anticancer drug development. Inhibitors under clinical investigation include agents that either block the ATP-binding site of ERK or disrupt its interaction with substrates and scaffold proteins, thereby attenuating downstream oncogenic signaling (martinvega2023navigatingtheerk12 pages 45-46, roberts2007targetingtherafmekerk pages 2-3).

In terms of disease associations, dysregulation of ERK1 plays a major role in several cancers, as well as in developmental disorders that arise from abnormal MAPK/ERK signaling. Alterations in the activity of ERK1 can lead to imbalances in cell proliferation, apoptosis, and differentiation, contributing to the oncogenic process. The extensive substrate repertoire and multiple regulatory mechanisms of ERK1 underscore its significance in both normal cellular physiology and pathological states (wang2007mitogenactivatedproteinkinases pages 1-2, coulombe2007atypicalmitogenactivatedprotein pages 1-2).

1. References
2. coulombe2007atypicalmitogenactivatedprotein pages 1-2
3. klomp2024determiningtheerkregulated pages 3-4
4. klomp2024determiningtheerkregulated pages 30-31
5. martinvega2023navigatingtheerk12 pages 1-2
6. martinvega2023navigatingtheerk12 pages 33-34
7. martinvega2023navigatingtheerk12 pages 4-5
8. roberts2007targetingtherafmekerk pages 1-2
9. wang2007mitogenactivatedproteinkinases pages 1-2
10. klomp2024determiningtheerkregulated pages 11-13
11. klomp2024determiningtheerkregulated pages 31-32
12. klomp2024determiningtheerkregulated pages 8-9
13. krishna2008thecomplexityof pages 1-2
14. krishna2008thecomplexityof pages 10-12
15. krishna2008thecomplexityof pages 2-4
16. manzoor2012mitogenactivatedproteinkinases pages 3-5
17. martinvega2023navigatingtheerk12 pages 30-32
18. martinvega2023navigatingtheerk12 pages 32-33
19. martinvega2023navigatingtheerk12 pages 33-34
20. martinvega2023navigatingtheerk12 pages 45-46
21. martinvega2023navigatingtheerk12 pages 5-7
22. martinvega2023navigatingtheerk12 pages 8-10
23. meloche2007theerk12mitogenactivated pages 13-13
24. pearson2001mitogenactivatedprotein(map) pages 2-3
25. pearson2001mitogenactivatedprotein(map) pages 4-4
26. roberts2007targetingtherafmekerk pages 2-3
27. roberts2007targetingtherafmekerk pages 3-5
28. champion2004reassessingthemap3k pages 6-6
29. coulombe2007atypicalmitogenactivatedprotein pages 11-12
30. eldarfinkelman2009peptideinhibitorstargeting pages 5-6
31. klomp2024determiningtheerkregulated pages 4-6
32. klomp2024determiningtheerkregulated pages 6-8
33. klomp2024determiningtheerkregulated pages 9-11
34. krishna2008thecomplexityof pages 13-14
35. lei2014mitogenactivatedproteinkinase pages 1-2
36. pearson2001mitogenactivatedprotein(map) pages 15-16
37. pearson2001mitogenactivatedprotein(map) pages 2-2

References

1. (coulombe2007atypicalmitogenactivatedprotein pages 1-2): Phillipe Coulombe and Sylvain Meloche. Atypical mitogen-activated protein kinases: structure, regulation and functions. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1773:1376-1387, Aug 2007. URL: https://doi.org/10.1016/j.bbamcr.2006.11.001, doi:10.1016/j.bbamcr.2006.11.001. This article has 462 citations.
2. (klomp2024determiningtheerkregulated pages 3-4): Jennifer E. Klomp, J. Nathaniel Diehl, Jeffrey A. Klomp, A. Cole Edwards, Runying Yang, Alexis J. Morales, Khalilah E. Taylor, Kristina Drizyte-Miller, Kirsten L. Bryant, Antje Schaefer, Jared L. Johnson, Emily M. Huntsman, Tomer M. Yaron, Mariaelena Pierobon, Elisa Baldelli, Alex W. Prevatte, Natalie K. Barker, Laura E. Herring, Emanuel F. Petricoin, Lee M. Graves, Lewis C. Cantley, Adrienne D. Cox, Channing J. Der, and Clint A. Stalnecker. Determining the erk-regulated phosphoproteome driving kras-mutant cancer. Science, Jun 2024. URL: https://doi.org/10.1126/science.adk0850, doi:10.1126/science.adk0850. This article has 27 citations and is from a highest quality peer-reviewed journal.
3. (klomp2024determiningtheerkregulated pages 30-31): Jennifer E. Klomp, J. Nathaniel Diehl, Jeffrey A. Klomp, A. Cole Edwards, Runying Yang, Alexis J. Morales, Khalilah E. Taylor, Kristina Drizyte-Miller, Kirsten L. Bryant, Antje Schaefer, Jared L. Johnson, Emily M. Huntsman, Tomer M. Yaron, Mariaelena Pierobon, Elisa Baldelli, Alex W. Prevatte, Natalie K. Barker, Laura E. Herring, Emanuel F. Petricoin, Lee M. Graves, Lewis C. Cantley, Adrienne D. Cox, Channing J. Der, and Clint A. Stalnecker. Determining the erk-regulated phosphoproteome driving kras-mutant cancer. Science, Jun 2024. URL: https://doi.org/10.1126/science.adk0850, doi:10.1126/science.adk0850. This article has 27 citations and is from a highest quality peer-reviewed journal.
4. (martinvega2023navigatingtheerk12 pages 1-2): Ana Martin-Vega and Melanie H. Cobb. Navigating the erk1/2 mapk cascade. Biomolecules, 13:1555, Oct 2023. URL: https://doi.org/10.3390/biom13101555, doi:10.3390/biom13101555. This article has 57 citations and is from a peer-reviewed journal.
5. (martinvega2023navigatingtheerk12 pages 33-34): Ana Martin-Vega and Melanie H. Cobb. Navigating the erk1/2 mapk cascade. Biomolecules, 13:1555, Oct 2023. URL: https://doi.org/10.3390/biom13101555, doi:10.3390/biom13101555. This article has 57 citations and is from a peer-reviewed journal.
6. (martinvega2023navigatingtheerk12 pages 4-5): Ana Martin-Vega and Melanie H. Cobb. Navigating the erk1/2 mapk cascade. Biomolecules, 13:1555, Oct 2023. URL: https://doi.org/10.3390/biom13101555, doi:10.3390/biom13101555. This article has 57 citations and is from a peer-reviewed journal.
7. (roberts2007targetingtherafmekerk pages 1-2): P J Roberts and C J Der. Targeting the raf-mek-erk mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 26:3291-3310, May 2007. URL: https://doi.org/10.1038/sj.onc.1210422, doi:10.1038/sj.onc.1210422. This article has 3605 citations and is from a domain leading peer-reviewed journal.
8. (wang2007mitogenactivatedproteinkinases pages 1-2): Yibin Wang. Mitogen-activated protein kinases in heart development and diseases. Circulation, 116:1413-1423, Sep 2007. URL: https://doi.org/10.1161/circulationaha.106.679589, doi:10.1161/circulationaha.106.679589. This article has 422 citations and is from a highest quality peer-reviewed journal.
9. (klomp2024determiningtheerkregulated pages 11-13): Jennifer E. Klomp, J. Nathaniel Diehl, Jeffrey A. Klomp, A. Cole Edwards, Runying Yang, Alexis J. Morales, Khalilah E. Taylor, Kristina Drizyte-Miller, Kirsten L. Bryant, Antje Schaefer, Jared L. Johnson, Emily M. Huntsman, Tomer M. Yaron, Mariaelena Pierobon, Elisa Baldelli, Alex W. Prevatte, Natalie K. Barker, Laura E. Herring, Emanuel F. Petricoin, Lee M. Graves, Lewis C. Cantley, Adrienne D. Cox, Channing J. Der, and Clint A. Stalnecker. Determining the erk-regulated phosphoproteome driving kras-mutant cancer. Science, Jun 2024. URL: https://doi.org/10.1126/science.adk0850, doi:10.1126/science.adk0850. This article has 27 citations and is from a highest quality peer-reviewed journal.
10. (klomp2024determiningtheerkregulated pages 31-32): Jennifer E. Klomp, J. Nathaniel Diehl, Jeffrey A. Klomp, A. Cole Edwards, Runying Yang, Alexis J. Morales, Khalilah E. Taylor, Kristina Drizyte-Miller, Kirsten L. Bryant, Antje Schaefer, Jared L. Johnson, Emily M. Huntsman, Tomer M. Yaron, Mariaelena Pierobon, Elisa Baldelli, Alex W. Prevatte, Natalie K. Barker, Laura E. Herring, Emanuel F. Petricoin, Lee M. Graves, Lewis C. Cantley, Adrienne D. Cox, Channing J. Der, and Clint A. Stalnecker. Determining the erk-regulated phosphoproteome driving kras-mutant cancer. Science, Jun 2024. URL: https://doi.org/10.1126/science.adk0850, doi:10.1126/science.adk0850. This article has 27 citations and is from a highest quality peer-reviewed journal.
11. (klomp2024determiningtheerkregulated pages 8-9): Jennifer E. Klomp, J. Nathaniel Diehl, Jeffrey A. Klomp, A. Cole Edwards, Runying Yang, Alexis J. Morales, Khalilah E. Taylor, Kristina Drizyte-Miller, Kirsten L. Bryant, Antje Schaefer, Jared L. Johnson, Emily M. Huntsman, Tomer M. Yaron, Mariaelena Pierobon, Elisa Baldelli, Alex W. Prevatte, Natalie K. Barker, Laura E. Herring, Emanuel F. Petricoin, Lee M. Graves, Lewis C. Cantley, Adrienne D. Cox, Channing J. Der, and Clint A. Stalnecker. Determining the erk-regulated phosphoproteome driving kras-mutant cancer. Science, Jun 2024. URL: https://doi.org/10.1126/science.adk0850, doi:10.1126/science.adk0850. This article has 27 citations and is from a highest quality peer-reviewed journal.
12. (krishna2008thecomplexityof pages 1-2): M. Krishna and H. Narang. The complexity of mitogen-activated protein kinases (mapks) made simple. Cellular and Molecular Life Sciences, 65:3525-3544, Aug 2008. URL: https://doi.org/10.1007/s00018-008-8170-7, doi:10.1007/s00018-008-8170-7. This article has 581 citations and is from a domain leading peer-reviewed journal.
13. (krishna2008thecomplexityof pages 10-12): M. Krishna and H. Narang. The complexity of mitogen-activated protein kinases (mapks) made simple. Cellular and Molecular Life Sciences, 65:3525-3544, Aug 2008. URL: https://doi.org/10.1007/s00018-008-8170-7, doi:10.1007/s00018-008-8170-7. This article has 581 citations and is from a domain leading peer-reviewed journal.
14. (krishna2008thecomplexityof pages 2-4): M. Krishna and H. Narang. The complexity of mitogen-activated protein kinases (mapks) made simple. Cellular and Molecular Life Sciences, 65:3525-3544, Aug 2008. URL: https://doi.org/10.1007/s00018-008-8170-7, doi:10.1007/s00018-008-8170-7. This article has 581 citations and is from a domain leading peer-reviewed journal.
15. (manzoor2012mitogenactivatedproteinkinases pages 3-5): Zahid Manzoor and Young-Sang Koh. Mitogen-activated protein kinases in inflammation. Journal of Bacteriology and Virology, 42:189-195, Sep 2012. URL: https://doi.org/10.4167/jbv.2012.42.3.189, doi:10.4167/jbv.2012.42.3.189. This article has 82 citations.
16. (martinvega2023navigatingtheerk12 pages 30-32): Ana Martin-Vega and Melanie H. Cobb. Navigating the erk1/2 mapk cascade. Biomolecules, 13:1555, Oct 2023. URL: https://doi.org/10.3390/biom13101555, doi:10.3390/biom13101555. This article has 57 citations and is from a peer-reviewed journal.
17. (martinvega2023navigatingtheerk12 pages 32-33): Ana Martin-Vega and Melanie H. Cobb. Navigating the erk1/2 mapk cascade. Biomolecules, 13:1555, Oct 2023. URL: https://doi.org/10.3390/biom13101555, doi:10.3390/biom13101555. This article has 57 citations and is from a peer-reviewed journal.
18. (martinvega2023navigatingtheerk12 pages 45-46): Ana Martin-Vega and Melanie H. Cobb. Navigating the erk1/2 mapk cascade. Biomolecules, 13:1555, Oct 2023. URL: https://doi.org/10.3390/biom13101555, doi:10.3390/biom13101555. This article has 57 citations and is from a peer-reviewed journal.
19. (martinvega2023navigatingtheerk12 pages 5-7): Ana Martin-Vega and Melanie H. Cobb. Navigating the erk1/2 mapk cascade. Biomolecules, 13:1555, Oct 2023. URL: https://doi.org/10.3390/biom13101555, doi:10.3390/biom13101555. This article has 57 citations and is from a peer-reviewed journal.
20. (martinvega2023navigatingtheerk12 pages 8-10): Ana Martin-Vega and Melanie H. Cobb. Navigating the erk1/2 mapk cascade. Biomolecules, 13:1555, Oct 2023. URL: https://doi.org/10.3390/biom13101555, doi:10.3390/biom13101555. This article has 57 citations and is from a peer-reviewed journal.
21. (meloche2007theerk12mitogenactivated pages 13-13): S. Meloche and J. Pouysségur. The erk1/2 mitogen-activated protein kinase pathway as a master regulator of the g1- to s-phase transition. Oncogene, 26:3227-3239, May 2007. URL: https://doi.org/10.1038/sj.onc.1210414, doi:10.1038/sj.onc.1210414. This article has 1419 citations and is from a domain leading peer-reviewed journal.
22. (pearson2001mitogenactivatedprotein(map) pages 2-3): Gray Pearson, Fred Robinson, Tara Beers Gibson, Bing-e Xu, Mahesh Karandikar, Kevin Berman, and Melanie H. Cobb. Mitogen-activated protein (map) kinase pathways: regulation and physiological functions\*. Endocrine Reviews, 22:153-183, Apr 2001. URL: https://doi.org/10.1210/edrv.22.2.0428, doi:10.1210/edrv.22.2.0428. This article has 4147 citations and is from a domain leading peer-reviewed journal.
23. (pearson2001mitogenactivatedprotein(map) pages 4-4): Gray Pearson, Fred Robinson, Tara Beers Gibson, Bing-e Xu, Mahesh Karandikar, Kevin Berman, and Melanie H. Cobb. Mitogen-activated protein (map) kinase pathways: regulation and physiological functions\*. Endocrine Reviews, 22:153-183, Apr 2001. URL: https://doi.org/10.1210/edrv.22.2.0428, doi:10.1210/edrv.22.2.0428. This article has 4147 citations and is from a domain leading peer-reviewed journal.
24. (roberts2007targetingtherafmekerk pages 2-3): P J Roberts and C J Der. Targeting the raf-mek-erk mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 26:3291-3310, May 2007. URL: https://doi.org/10.1038/sj.onc.1210422, doi:10.1038/sj.onc.1210422. This article has 3605 citations and is from a domain leading peer-reviewed journal.
25. (roberts2007targetingtherafmekerk pages 3-5): P J Roberts and C J Der. Targeting the raf-mek-erk mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 26:3291-3310, May 2007. URL: https://doi.org/10.1038/sj.onc.1210422, doi:10.1038/sj.onc.1210422. This article has 3605 citations and is from a domain leading peer-reviewed journal.
26. (champion2004reassessingthemap3k pages 6-6): Antony Champion, Alain Picaud, and Yves Henry. Reassessing the map3k and map4k relationships. Trends in Plant Science, 9:123-129, Mar 2004. URL: https://doi.org/10.1016/j.tplants.2004.01.005, doi:10.1016/j.tplants.2004.01.005. This article has 115 citations and is from a domain leading peer-reviewed journal.
27. (coulombe2007atypicalmitogenactivatedprotein pages 11-12): Phillipe Coulombe and Sylvain Meloche. Atypical mitogen-activated protein kinases: structure, regulation and functions. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1773:1376-1387, Aug 2007. URL: https://doi.org/10.1016/j.bbamcr.2006.11.001, doi:10.1016/j.bbamcr.2006.11.001. This article has 462 citations.
28. (eldarfinkelman2009peptideinhibitorstargeting pages 5-6): Hagit Eldar-Finkelman and Miriam Eisenstein. Peptide inhibitors targeting protein kinases. Current Pharmaceutical Design, 15:2463-2470, Jul 2009. URL: https://doi.org/10.2174/138161209788682253, doi:10.2174/138161209788682253. This article has 109 citations and is from a peer-reviewed journal.
29. (klomp2024determiningtheerkregulated pages 4-6): Jennifer E. Klomp, J. Nathaniel Diehl, Jeffrey A. Klomp, A. Cole Edwards, Runying Yang, Alexis J. Morales, Khalilah E. Taylor, Kristina Drizyte-Miller, Kirsten L. Bryant, Antje Schaefer, Jared L. Johnson, Emily M. Huntsman, Tomer M. Yaron, Mariaelena Pierobon, Elisa Baldelli, Alex W. Prevatte, Natalie K. Barker, Laura E. Herring, Emanuel F. Petricoin, Lee M. Graves, Lewis C. Cantley, Adrienne D. Cox, Channing J. Der, and Clint A. Stalnecker. Determining the erk-regulated phosphoproteome driving kras-mutant cancer. Science, Jun 2024. URL: https://doi.org/10.1126/science.adk0850, doi:10.1126/science.adk0850. This article has 27 citations and is from a highest quality peer-reviewed journal.
30. (klomp2024determiningtheerkregulated pages 6-8): Jennifer E. Klomp, J. Nathaniel Diehl, Jeffrey A. Klomp, A. Cole Edwards, Runying Yang, Alexis J. Morales, Khalilah E. Taylor, Kristina Drizyte-Miller, Kirsten L. Bryant, Antje Schaefer, Jared L. Johnson, Emily M. Huntsman, Tomer M. Yaron, Mariaelena Pierobon, Elisa Baldelli, Alex W. Prevatte, Natalie K. Barker, Laura E. Herring, Emanuel F. Petricoin, Lee M. Graves, Lewis C. Cantley, Adrienne D. Cox, Channing J. Der, and Clint A. Stalnecker. Determining the erk-regulated phosphoproteome driving kras-mutant cancer. Science, Jun 2024. URL: https://doi.org/10.1126/science.adk0850, doi:10.1126/science.adk0850. This article has 27 citations and is from a highest quality peer-reviewed journal.
31. (klomp2024determiningtheerkregulated pages 9-11): Jennifer E. Klomp, J. Nathaniel Diehl, Jeffrey A. Klomp, A. Cole Edwards, Runying Yang, Alexis J. Morales, Khalilah E. Taylor, Kristina Drizyte-Miller, Kirsten L. Bryant, Antje Schaefer, Jared L. Johnson, Emily M. Huntsman, Tomer M. Yaron, Mariaelena Pierobon, Elisa Baldelli, Alex W. Prevatte, Natalie K. Barker, Laura E. Herring, Emanuel F. Petricoin, Lee M. Graves, Lewis C. Cantley, Adrienne D. Cox, Channing J. Der, and Clint A. Stalnecker. Determining the erk-regulated phosphoproteome driving kras-mutant cancer. Science, Jun 2024. URL: https://doi.org/10.1126/science.adk0850, doi:10.1126/science.adk0850. This article has 27 citations and is from a highest quality peer-reviewed journal.
32. (krishna2008thecomplexityof pages 13-14): M. Krishna and H. Narang. The complexity of mitogen-activated protein kinases (mapks) made simple. Cellular and Molecular Life Sciences, 65:3525-3544, Aug 2008. URL: https://doi.org/10.1007/s00018-008-8170-7, doi:10.1007/s00018-008-8170-7. This article has 581 citations and is from a domain leading peer-reviewed journal.
33. (lei2014mitogenactivatedproteinkinase pages 1-2): Yuan-Yuan Lei, Wei-Jia Wang, Jin-Hong Mei, and Chun-Liang Wang. Mitogen-activated protein kinase signal transduction in solid tumors. Asian Pacific Journal of Cancer Prevention, 15:8539-8548, Nov 2014. URL: https://doi.org/10.7314/apjcp.2014.15.20.8539, doi:10.7314/apjcp.2014.15.20.8539. This article has 159 citations and is from a peer-reviewed journal.
34. (martinvega2023navigatingtheerk12 pages 7-8): Ana Martin-Vega and Melanie H. Cobb. Navigating the erk1/2 mapk cascade. Biomolecules, 13:1555, Oct 2023. URL: https://doi.org/10.3390/biom13101555, doi:10.3390/biom13101555. This article has 57 citations and is from a peer-reviewed journal.
35. (pearson2001mitogenactivatedprotein(map) pages 1-2): Gray Pearson, Fred Robinson, Tara Beers Gibson, Bing-e Xu, Mahesh Karandikar, Kevin Berman, and Melanie H. Cobb. Mitogen-activated protein (map) kinase pathways: regulation and physiological functions\*. Endocrine Reviews, 22:153-183, Apr 2001. URL: https://doi.org/10.1210/edrv.22.2.0428, doi:10.1210/edrv.22.2.0428. This article has 4147 citations and is from a domain leading peer-reviewed journal.
36. (pearson2001mitogenactivatedprotein(map) pages 15-16): Gray Pearson, Fred Robinson, Tara Beers Gibson, Bing-e Xu, Mahesh Karandikar, Kevin Berman, and Melanie H. Cobb. Mitogen-activated protein (map) kinase pathways: regulation and physiological functions\*. Endocrine Reviews, 22:153-183, Apr 2001. URL: https://doi.org/10.1210/edrv.22.2.0428, doi:10.1210/edrv.22.2.0428. This article has 4147 citations and is from a domain leading peer-reviewed journal.
37. (pearson2001mitogenactivatedprotein(map) pages 2-2): Gray Pearson, Fred Robinson, Tara Beers Gibson, Bing-e Xu, Mahesh Karandikar, Kevin Berman, and Melanie H. Cobb. Mitogen-activated protein (map) kinase pathways: regulation and physiological functions\*. Endocrine Reviews, 22:153-183, Apr 2001. URL: https://doi.org/10.1210/edrv.22.2.0428, doi:10.1210/edrv.22.2.0428. This article has 4147 citations and is from a domain leading peer-reviewed journal.